Johnson & Johnson (JNJ)
Johnson & Johnson (JNJ) Stock Dips While Market Gains: Key Facts
Johnson & Johnson (JNJ) reached $174.16 at the closing of the latest trading day, reflecting a -1.72% change compared to its last close.
J&J Expects Innovative Medicines Growth Despite Stelara LOE: Here's Why
J&J sees Innovative Medicines growth in 2025, fueled by oncology and immunology drugs, despite steep Stelara sales erosion.
3 Dividend Stocks to Hold Through Market Volatility This Fall
Stocks are rallying on the expectation that the Federal Reserve will cut interest rates by 25 basis points in September. That should be positive for corporate earnings.
JNJ Seeks EU Approval for Oral Psoriasis Drug Icotrokinra
J&J seeks EMA's nod to icotrokinra for treating plaque psoriasis in adults and pediatric patients aged 12 years and older.
Are You Looking for a High-Growth Dividend Stock?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Johnson & Johnson: A 6.9 Rating and What It Means for Investors
Explore the exciting world of Johnson & Johnson (JNJ -0.31%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
Johnson & Johnson (JNJ) Presents At 2025 Wells Fargo Healthcare Conference (Transcript)
Johnson & Johnson (NYSE:JNJ ) 2025 Wells Fargo Healthcare Conference September 3, 2025 11:50 AM EDT Company Participants Tim Schmid - Executive VP & Worldwide Chairman of MedTech Conference Call Participants Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Presentation Larry Biegelsen Senior Medical Device Equity Research Analyst Okay. Are we ready to go.
J&J Ends Imaavy Development in Rheumatoid Arthritis Post Study Failure
JNJ halts Imaavy's rheumatoid arthritis program after trial results showed no added benefit over existing therapy.
J&J Stock Trading Above 200 & 50 Day SMA for 2 Months: Time to Buy?
Johnson & Johnson stock surges above key moving averages as strong results, raised guidance and growth prospects fuel momentum.
JNJ Stock Surge Signals Confidence in New Growth Path
Johnson & Johnson's NYSE: JNJ stock chart is sending a clear signal that contrasts sharply with the persistent hum of repetitive negative headlines. While news cycles continue to circle long-running legal battles, the company's market performance paints a picture of investor confidence, with its stock climbing over 23% year-to-date.
2 Dividend Stocks Worth Doubling Down on Right Now
Dividend stocks aren't all created equal. Some decrease their payouts, or suspend them altogether, when they face headwinds.
Johnson & Johnson to invest $2B in North Carolina plant as Trump's 250% drug tariffs loom
It's a move to boost its domestic production as President Donald Trump threatens to slap devastating tariffs on pharmaceutical imports.
